Table 1 Baseline characteristics of the population before and after propensity score matching
Whole study population | Matched population | |||||||
|---|---|---|---|---|---|---|---|---|
FOLFIRINOX (n = 371) | Gemcitabine/nab-paclitaxel (n = 157) | P value | SMD | FOLFIRINOX (n = 151) | Gemcitabine/nab-paclitaxel (n = 151) | P value | SMD | |
Age (years) | 61 (54–67) | 64 (57–71) | < 0.001 | 0.38 | 62 (57–70) | 64 (57–70) | 0.39 | 0.05 |
Sex, male | 229 (61.7) | 94 (59.9) | 0.69 | 0.04 | 84 (55.6) | 91 (60.3) | 0.42 | − 0.09 |
ECOG-PS | 0.15 | −0.07 | 0.90 | 0.03 | ||||
0 | 64 (17.3) | 34 (21.7) | 33 (21.9) | 32 (21.2) | ||||
1 | 305 (82.2) | 120 (76.4) | 116 (76.8) | 116 (76.8) | ||||
2 | 2 (0.5) | 3 (1.9) | 2 (1.3) | 3 (2.0) | ||||
Tumor sizea | 3.7 (3.0–4.8) | 4.0 (2.6–5.3) | 0.41 | 0.09 | 4.0 (3.0–4.8) | 3.9 (2.5–5.0) | 0.92 | 0.02 |
Tumor locationa | 0.07 | −0.06 | 0.63 | −0.01 | ||||
Head/uncinate | 115 (37.5) | 33 (28.2) | 37 (31.9) | 33 (28.9) | ||||
Body/tail | 192 (62.5) | 84 (72.4) | 79 (68.1) | 81 (71.1) | ||||
Previous curative surgery | 64 (17.3) | 40 (25.5) | 0.03 | 0.19 | 35 (23.2) | 37 (24.5) | 0.79 | 0.03 |
Number of metastatic sites | 0.15 | 0.09 | 0.78 | −0.07 | ||||
1 | 233 (62.8) | 97 (61.8) | 88 (58.3) | 94 (62.3) | ||||
2 | 97 (26.1) | 34 (21.7) | 37 (24.5) | 33 (21.9) | ||||
3 or more | 41 (11.1) | 26 (16.6) | 26 (17.2) | 24 (15.9) | ||||
Metastatic sites | ||||||||
Liver metastases | 234 (63.1) | 90 (57.3) | 0.20 | −0.12 | 88 (58.3) | 87 (57.6) | 0.91 | −0.01 |
Peritoneal seeding | 100 (27.0) | 57 (36.3) | 0.03 | 0.19 | 53 (35.1) | 53 (35.1) | 1 | 0 |
Lung metastases | 59 (15.9) | 38 (24.2) | 0.02 | 0.19 | 35 (23.2) | 35 (23.2) | 1 | 0 |
Distant lymph node | 125 (33.7) | 51 (32.5) | 0.79 | −0.03 | 51 (33.8) | 49 (32.5) | 0.81 | −0.03 |
Other (bone, adrenal) | 38 (10.2) | 22 (14.0) | 0.20 | 0.11 | 16 (10.6) | 20 (13.2) | 0.48 | 0.08 |
Laboratory findings | ||||||||
WBC (cells/uL) | 6.8 (5.6–8.7) | 6.6 (5.1–8.4) | 0.22 | −0.09 | 6.8 (5.6–8.4) | 6.6 (5.1–8.4) | 0.687 | −0.05 |
Hb (g/dL) | 12.5 (11.3–13.7) | 12.2 (11.1–13.1) | 0.03 | −0.19 | 12 (11–13) | 12 (11–13) | 0.583 | 0.09 |
PLT (× 103 cells/uL) | 233 (185–286) | 226 (182–287) | 0.49 | −0.04 | 235 (189–287) | 224 (180–287) | 0.338 | −0.09 |
Bilirubin (mg/dL) | 0.6 (0.4–0.9) | 0.6 (0.5–0.8) | 0.28 | −0.07 | 0.6 (0.4–1.0) | 0.6 (0.5–0.8) | 0.873 | −0.07 |
ALP (IU/L) | 82 (68–146) | 89 (72–123) | 0.45 | −0.06 | 88 (66–130) | 89 (72–123) | 0.874 | −0.01 |
Albumin (g/dL) | 3.9 (3.6–4.2) | 4.0 (3.7–4.2) | 0.50 | 0.02 | 3.9 (3.6–4.2) | 4.0 (3.7–4.2) | 0.195 | 0.09 |
CA 19–9 (U/mL) | 1010 (121–5710) | 938 (115–5320) | 0.80 | −0.54 | 676 (58–4560) | 937 (115–5740) | 0.481 | −0.02 |